Technology Offer

CIBER-BBN’s exploitable technology patent portfolio is available to companies and organizations to promote its transfer to the industrial sector, generate collaborative technological development projects and favour the use of the research results.

Each of the “technological specification sheets” describes a technology, its industrial application and innovative advantages, among other aspects. Said information can be expanded through the contact shown in each of them.


An accurate localization of epileptogenic the focus in patients with intractable focal seizures is essential to ensure success in surgical treatment.

The SISCOM (Subtraction Ictal SPECT Co of-registered to MRI) methodology is one of the techniques used to localize the epileptogenic focus that combines functional information from ictal and interictal SPECT (Single Photon Emission Computed Tomography) studies with anatomical information from an MRI (Magnetic Resonance Imaging).

The SISCOM Analysis plu-gin of FocusDET is a new research-oriented tool to perform SISCOM methodology in a user friendly interface in a unique environment.

FocusDET has been developed by using the GIMIAS framework ( within an intramural CIBER-BBN project, the Virtual Physiological Human Toolkit (VPHTK). The following groups participated in the development of FocusDET: 1) Biomedical Imaging Group at the Universitat de Barcelona (GIB-UB), 2) Biomedical Imaging Technology at Universidad Politecnica de Madridd (BIT-UPM) and 3) Computational Imaging and Simulation Technology in Biomedicine at Universitat Pompeu Fabra (CISTIB-UPF).

More information

Here you will find our offers and requests for technology that are available for collaboration with companies. If you need any further information or have a particular technological issue to address, please contact us at We are open to different kinds of collaboration.

CIBERES's Technology Offer

1. New antibiotics. Unique compounds targeting DNA Topoisomerase1

Seconeolitsine and Nmethyl-seconeolitsine compounds work in in the low µM concentration range against S. pneumoniae and other bacteria displaying multiple resistance, with more protective action than fluoroquinolones.

2. New compounds useful in the treatment of inflammatory diseases progressing through cell apoptosis and fibrosis

These compounds are useful for preparing pharmaceutical formulations targeting inflammatory diseases progressing through cell apoptosis and fibrosis, such us sepsis, ALI induced by sepsis, ARDS induced by sepsis, endotoxic shock, endotoxemia, trauma or tissue damage.

3. New broad-spectrum enzybiotics with enhanced activity

Sequence and synthesis of polypeptides with enhanced binding capacity and activity for the use against pneumococcus and other Gram-positive and Gram negative bacteria.

4. Quick method to assess if different isolates of M. Tuberculosis have the same clone origin and if they are resistant to rifampicin and isoniazid

Based in IS6110 (Gold standard), offers quick results (few hours), is automated, standardized and reproducible. If widely adopted, this technology would allow better control of TB. The technology can be used to identify strains resistant to rifampicin and isoniazid and can be extended to other bacteria with specific IS.

5. Set of miRNAs as markers for the diagnosis of Diffuse Alveolar Damage (DAD)

Set of miRNAs which expression identifies, in serum sample of patients, the presence of DAD with a specificity higher than 75%. The method could be a diagnosis tool for DAD for all the health conditions with a high risk to develop it and a confirmation tool for those patients with clinical suspicion of ARDS.

6. Nanoparticles for cancer therapies

The invention refers to micelles that contain nanoparticles with an iron‐oxide, UCNP or metal core, surrounded by an outer organic layer and coated with glycoside derivatives with antitumor activity. These nanoparticles permit the solubility in water of insoluble compounds and the use of a magnetic field in order to concentrate them in a specific area.

7. Test for predicting blood pressure response to continuous positive air pressure treatment (CPAP) in patients with resistant hypertension

A test based in a set of miRNAs which expression in plasma can predict blood pressure response to CPAP treatment for patients with resistant hypertension that do not respond to any other treatment. This method can identify, with high sensitivity and specific values, patients that can positively benefit from CPAP treatment for their resistant hypertension.

8. Bimodal liposomes for pet and optical imaging of tumors

These bimodal labelled liposomes enable simultaneous PET and intraoperative optical imaging to non-invasively visualize the biodistribution and disease targeting of liposomal therapeutics. They match long circulation time with high stability. Moreover, these nanoparticles accumulate in areas with leaky vasculature through the enhanced permeability and retention (EPR) effect. They can be used to detect and delineate malignant growth, inflammation, and infection in diverse disease contexts and are of high value as a theranostic platform.

9. New control system for oxygenotherapy

The new device offers a variable oxygen flow depending on the physical work and other physiological parameters. It has a wireless design compatible with telemetry and is a user-friendly and portable. It anticipates oxygen demand before having signs of oxygen desaturation. Validated for patients with idiopathic pulmonary fibrosis (IPF).

10.  Concentration and detection of microorganisms, through a watertight compartment device and procedure. 

Filter-integrated system, that allows, in one device, both concentration and detection of microorganisms. The system, that could be reusable or disposable, maintains tightness during concentration and detection, ensures a homogeneous distribution of the sample in the membrane, and the mixing of reagents though the reaction chamber and a peristaltic pump.   The analytical device allows detection and measurement of said microorganisms by affinity methods using recognition proteins such as antibodies by immunological methods.

In this area you can consult our technology supply and demand available for cooperation with business.

CIBEROBN has the following Technology Range available for you:

Technology range of the CIBEREHD:

  • Topical composition for the treatment of mucosal lesions and skin ulcers.
  • Composition for relief, improvement, prevention and/or treatment of Hepatitis C.
  • Method for the prognosis of hepatocellular carcinoma.
  • Method for obtaining useful data for the diagnosis of hepatocarcinoma in alcoholic patients with hepatitis C.
  • Use of derivatives of anthranilic acid in the preparation of a drug for treatment of cholestasis.
  • Use of aureolic acid derivatives in preparing a drug for treatment of cholestasis.
  • Computerized optical analysis methods of MR (magnetic resonance) images for quantifying or determining liver lesions.
  • Method for obtaining data useful for prediction or prognosis of chronification of hepatitis C and clarifying of HCV.
  • Method for obtaining useful data for predicting or prognosis of vertical transmission of the hepatitis C virus.
  • Method for obtaining data useful for the diagnosis of hepatocarcinoma in alcoholic patients with hepatitis C by means of four markers.

In this area you can consult our technology supply and demand available for cooperation with business.